CG0070

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bladder Cancer

Conditions

Bladder Cancer

Trial Timeline

Jun 2, 2015 → Feb 1, 2019

About CG0070

CG0070 is a phase 2 stage product being developed by CG Oncology for Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02365818. Target conditions include Bladder Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02365818Phase 2Completed

Competing Products

20 competing products in Bladder Cancer

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
EG-70 (phase 1) + EG-70 (phase 2)enGenePhase 1/2
33
mirabegron + solifenacinAstellas PharmaApproved
85
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
MK-3475 + ASG-22CEAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33